Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 2045-2053

  Tzeng, Ching Wei D ^a   Fleming, Jason B ^a   Lee, Jeffrey E ^a   Xiao, Lianchun ^a   Pisters, Peter W T ^a   Vauthey, Jean Nicolas ^a   Abdalla, Eddie K ^a   Wolff, Robert A ^a   Varadhachary, Gauri R ^a   Fogelman, David R ^a   Crane, Christopher H ^a   Balachandran, Aparna ^a   Katz, Matthew H G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PAIN ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PANCREAS RESECTION; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84865147618     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2211-4     Document Type: Article

References (34)

1. Katz MH, Hwang R, Fleming JB, Evans DB. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008;58:111-25. (Pubitemid 351521866)
2. Exocrine pancreas. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2009. p. 241-9.
3. Pancreatic adenocarcinoma version 2.2011. NCCN clinical practice guidelines in oncology, 2011. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp.
4. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. Am J Roentgenol. 1997;168:1439-43. (Pubitemid 27232661)
5. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-46. (Pubitemid 44337962)
6. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320-6. (Pubitemid 46536816)
7. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-80. (Pubitemid 47196512)
8. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocar-cinoma. Ann Surg Oncol. 2009;16:836-47.
9. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-9.
10. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3496-502.
11. Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradi-ation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol. 2000;18:860-7. (Pubitemid 30106618)
12. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20:2537-44. (Pubitemid 34525741)
13. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based che-moradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-95.
14. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46.
15. Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol. 2011;18:608-10.
16. Pisters PW, Hudec WA, Hess KR, et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 2001;234: 47-55. (Pubitemid 32619334)
17. Hwang RF, Wang H, Lara A, et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008;15:1356-66.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55. (Pubitemid 13149996)
19. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004;198:722-31. (Pubitemid 38542900)
20. Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adeno-carcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701-6.
21. Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampul-lary adenocarcinoma: 5-year survivors and their 6-to 10-year follow-up. Surgery. 2006;140:764-72. (Pubitemid 44648193)
22. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456-62.
23. Wayne JD, Abdalla EK, Wolff RA, Crane CH, Pisters PW, Evans DB. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist. 2002;7:34-45. (Pubitemid 34151106)
24. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adeno-carcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121-30. (Pubitemid 33652049)
25. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012;16:68-79.
26. Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) registry. Int J Radiat Oncol Biol Phys. 2008;72:1128-33.
27. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neo-adjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117:2044-9.
28. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adeno-carcinoma. J Am Coll Surg. 2008;206:451-7.
29. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adeno-carcinoma. J Clin Oncol. 1998;16:3843-50. (Pubitemid 29001537)
30. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009;13:752-9.
31. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195-200. (Pubitemid 27053441)
32. Aloia TA, Lee JE, Vauthey JN, et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007;204:347-55. (Pubitemid 46283494)
33. Barugola G, Partelli S, Marcucci S, et al. Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol. 2009;16:3316-22.
34. Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-801.